GlassScriptPhysician profile
Shadan Mansoor
NPI 1679523088
$2,802.90
in general payments reported to CMS, 2019-2025
34 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $323 · 2021: $160 · 2022: $185 · 2023: $727 · 2024: $688 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $296.77 | 2022-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $233.31 | 2019-2025 | Tecvayli, Talvey |
| Astellas Pharma US INC | $213.15 | 2019-2023 | Xospata |
| Novartis Pharmaceuticals Corporation | $197.40 | 2019-2025 | |
| Pfizer INC. | $152.58 | 2019-2024 | |
| Puma Biotechnology, INC. | $151.02 | 2021-2023 | |
| Gilead Sciences, INC. | $149.36 | 2021-2025 | Trodelvy |
| Amgen INC. | $142.06 | 2023 | Lumakras, Nplate, Xgeva |
| Abbvie INC. | $141.74 | 2023-2025 | |
| Exelixis INC. | $135.83 | 2019-2025 | Cabometyx |
| Blueprint Medicines Corporation | $118.68 | 2024 | Ayvakit |
| Glaxosmithkline, LLC. | $117.27 | 2022-2025 | Ojjaara, Jemperli, Blenrep |
| Genzyme Corporation | $115.68 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $85.94 | 2022-2024 | Eliquis, Opdualag |
| Array Biopharma INC | $70.12 | 2024-2025 | Mektovi, Braftovi, Xalkori |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $50.26 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $40.22 | 2019-2024 | Enhertu |
| Agios Pharmaceuticals, INC. | $39.89 | 2023-2024 | Pyrukynd |
| Tempus Ai, INC | $35.55 | 2024 | |
| Genentech USA, INC. | $35.42 | 2019-2023 | Tecentriq |
| Beone Medicines USA, INC. | $32.83 | 2025 | Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $25.84 | 2023 | Imbruvica, Epkinly |
| Beigene USA, INC. | $24.61 | 2020 | |
| Daiichi Sankyo INC. | $23.62 | 2024 | Enhertu |
| Aveo Pharmaceuticals, INC. | $22.21 | 2023 | Fotivda |
| Morphosys, US INC. | $21.20 | 2023 | Monjuvi |
| Mirati Therapeutics, INC. | $21.15 | 2023 | Krazati |
| Boston Scientific Corporation | $18.61 | 2022 | |
| Eisai INC. | $18.48 | 2023 | |
| Seagen INC. | $17.24 | 2023 | Padcev |
| Sobi, INC | $16.24 | 2024 | |
| Secura Bio, INC. | $14.19 | 2023 | Copiktra |
| Incyte Corporation | $12.46 | 2020 | |
| Acrotech Biopharma INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadan Mansoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.